Horizon Therapeutics Public - HZNP Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HZNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HZNP, but not buy additional shares or sell existing shares.
View HZNP analyst ratings or view top-rated stocks.

11 brokers have issued 1-year target prices for Horizon Therapeutics Public's stock. Their HZNP share price forecasts range from $71.00 to $144.00. On average, they predict the company's share price to reach $111.42 in the next year. This suggests a possible upside of 1.6% from the stock's current price.
View analysts price targets for HZNP or view top-rated stocks among Wall Street analysts.

Horizon Therapeutics Public's stock was trading at $113.80 at the beginning of the year. Since then, HZNP shares have decreased by 3.6% and is now trading at $109.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 1st 2023.
View our HZNP earnings forecast.

Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.21. The biopharmaceutical company earned $1.04 billion during the quarter, compared to the consensus estimate of $979.49 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 24.59% and a net margin of 15.51%. The company's revenue was up 62.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 EPS.

Horizon Therapeutics Public updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.59 billion-$3.61 billion, compared to the consensus revenue estimate of $3.56 billion.

70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Horizon Therapeutics Public's stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.58%), Bank of Montreal Can (0.36%), Strs Ohio (0.31%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Allspring Global Investments Holdings LLC (0.18%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Aaron Cox, Andy Pasternak, Barry Moze, Brian K Beeler, Brian K Beeler, Daniel A Camardo, Elizabeth HZ Thompson, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Paul W Hoelscher, Sean M Clayton, Timothy P Walbert, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends.

Shares of HZNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HZNP stock can currently be purchased for approximately $109.68.

Horizon Therapeutics Public (NASDAQ:HZNP) has a market capitalization of $24.86 billion and generates $3.23 billion in revenue each year. The biopharmaceutical company earns $534.49 million in net income (profit) each year or $2.44 on an earnings per share basis.

The company employs 1,890 workers across the globe.

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The official website for the company is www.horizontherapeutics.com. The biopharmaceutical company can be reached via phone at (531) 772-2100, via email at investor-relations@horizontherapeutics.com, or via fax at 224-383-3001.